Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07763665
Anti-inflammatory Effect of MgSO₄ in Patients With Moderate Traumatic Brain Injury by Measurming Nucleotide-binding Oligomerization Domain-Like Receptor Pyrin Domain-containing 3 (NLRP3) Inflammasome-a Multiprotein ComplexAssiut UniversityNot Yet RecruitingPhase 4
NCT07763665Not Yet Recruiting
Phase 4
Anti-inflammatory Effect of MgSO₄ in Patients With Moderate Traumatic Brain Inju...Assiut University
NCT07762066
Bridge to Belonging: Peer Led Intervention to Reduce Loneliness and Depression Among Older Gay and Bisexual MenFenway Community HealthRecruitingNot Applicable
NCT07762066Recruiting
Not Applicable
Bridge to Belonging: Peer Led Intervention to Reduce Loneliness and Depression A...Fenway Community Health
NCT07762495
Echocardiographic Molecular Imaging for POC Detection of IschemiaNational Heart, Lung, and Blood Institute (NHLBI)Not Yet RecruitingEarly Phase 1
NCT07762495Not Yet Recruiting
Early Phase 1
Echocardiographic Molecular Imaging for POC Detection of IschemiaNational Heart, Lung, and...
NCT07762976
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal CarcinomaFudan UniversityRecruitingPhase 2
NCT07762976Recruiting
Phase 2
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasoph...Fudan University
NCT07764081
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764081Recruiting
—
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, N...
NCT07764237
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsModernaTX, Inc.Not Yet RecruitingPhase 1
NCT07764237Not Yet Recruiting
Phase 1
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (...ModernaTX, Inc.
NCT07762885
Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryFudan UniversityRecruitingPhase 3
NCT07762885Recruiting
Phase 3
Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma...Fudan University
NCT07762378
Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic TherapyInstituto de Investigación Sanitaria Gregorio MarañónNot Yet RecruitingNot Applicable
NCT07762378Not Yet Recruiting
Not Applicable
Clinical Impact of a Machine Learning Decision Support System for Empirical Anti...Instituto de Investigació...
NCT07763899
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763899Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07763795
Effects of BFRT on Glycemic Control, Nerve Conduction, Functional Outcomes and QOL in Individuals With Type 2 DiabetesSuperior UniversityActive Not RecruitingNot Applicable
NCT07763795Active Not Recruiting
Not Applicable
Effects of BFRT on Glycemic Control, Nerve Conduction, Functional Outcomes and Q...Superior University
NCT07762963
Turkish Validation of the Core Life Activities ScaleTokat Gaziosmanpasa UniversityNot Yet Recruiting
NCT07762963Not Yet Recruiting
—
Turkish Validation of the Core Life Activities ScaleTokat Gaziosmanpasa Unive...
NCT07763496
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUPNot Yet RecruitingPhase 2
NCT07763496Not Yet Recruiting
Phase 2
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUP
NCT07762950
Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic PancreatitisChanghai HospitalNot Yet Recruiting
NCT07762950Not Yet Recruiting
—
Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancre...Changhai Hospital
NCT07763262
Autologous Nanofat Injection for Treatment of Stable VitiligoBenha UniversityCompletedNot Applicable
NCT07763262Completed
Not Applicable
Autologous Nanofat Injection for Treatment of Stable VitiligoBenha University
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07762898
Sedentary Behavior Intervention for Older Adults With Coronary Heart Disease and FrailtyGansu University of Chinese MedicineNot Yet RecruitingNot Applicable
NCT07762898Not Yet Recruiting
Not Applicable
Sedentary Behavior Intervention for Older Adults With Coronary Heart Disease and...Gansu University of Chine...
NCT07763522
Validation of a Methodology Using Isometric Dynamometer for Ankle STrength Assessment to Quantify LDH-induced ParesisHelsinki University Central HospitalEnrolling By InvitationNot Applicable
NCT07763522Enrolling By Invitation
Not Applicable
Validation of a Methodology Using Isometric Dynamometer for Ankle STrength Asses...Helsinki University Centr...
NCT07762924
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryFudan UniversityRecruitingPhase 2
NCT07762924Recruiting
Phase 2
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Fol...Fudan University
NCT07763743
Efficacy and Safety of Flexible Ureteroscopy With Flexible Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy With Vacuum-Assisted Access SheathAin Shams UniversityRecruitingNot Applicable
NCT07763743Recruiting
Not Applicable
Efficacy and Safety of Flexible Ureteroscopy With Flexible Navigable Suction Ure...Ain Shams University
Result Breakdown
Not yet recruiting8 (40%)
Recruiting6 (30%)
Completed3 (15%)
Active, not recruiting1 (5%)
Unknown1 (5%)
Enrolling by invitation1 (5%)
not_applicable8 (40%)
Not Specified5 (25%)
Phase 23 (15%)
Phase 41 (5%)
Early Phase 11 (5%)
Phase 11 (5%)
Phase 31 (5%)